Home > Events >

Conference: 4th Annual European Forum for Industrial Biotechnology and The Biobased Economy – EFIB

Published online: Mar 7, 2011

Event Title 4th Annual European Forum for Industrial Biotechnology and The Biobased Economy – EFIB
Date Oct 18, 2011 - Oct 20, 2011
Event Details
4th Annual European Forum for Industrial Biotechnology and The Biobased Economy – EFIB

18-20 October 2011 | Amsterdam, The Netherlands

EFIB is the market leading conference for the industrial biotechnology sector with the unrivalled line-up of speakers, prevailing exhibition and expanding year to year attendance.

2011 edition will cover topics such as the importance of the CAP for the Bio-based Economy, end users perspectives and market forecast, breakthroughs in industrial biotechnology and biorefinery research, implementing sustainability in sourcing and the value chain, innovative biobased products in the pipeline, sustainable feedstock for a sustainable biobased economy and the importance of the Bio-based Economy in the EU Innovation Policy discussed by the leading experts from the industry, policy-making bodies, NGOs and academia. Presenting companies include L’Oreal, RABO Bank, KLM, Danone, Genencor, Novozymes, DSM, DuPont, Evonik Degussa, Wacker Chemie, EU Commission, Copa-Cogeca and many more!

EFIB 2011 will feature pre-conference workshops, 2 plenary and 3 parallel sessions, exhibition and unparallel networking opportunities with over 400 attendees expected.

To find out more, log onto the website below.

Website http://www.efibforum.com/
Venue Novotel Amsterdam City Hotel
Novotel Amsterdam City Hotel
Europaboulevard 10
1083 AD
Amsterdam
The Netherlands
H0515@accor.com
Contact Details Ciaran Little
Pira
Cleeve Road
Leatherhead
Surrey
KT22 7RU
ciaran.little@pira-international.com
+44 (0)1372 802063

Tag this article

Please register and login to tag our features, news and patent summaries.


This article has not been tagged with keywords. Be the first to tag this article.



Comment on this article

Please register and login to comment on our features, news and patent summaries.


This article has not been commented on. Be the first to comment on this article.